EE165 Cost-Effectiveness Analysis of Liposomal Formulation of Daunorubicin and Cytarabine (CPX-351) for the Treatment of Adult Patients With Newly Diagnosed Therapy-Related AML or AML With Myelodysplasia-Related Changes in Greece
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.415
https://www.valueinhealthjournal.com/article/S1098-3015(22)02619-5/fulltext
Title :
EE165 Cost-Effectiveness Analysis of Liposomal Formulation of Daunorubicin and Cytarabine (CPX-351) for the Treatment of Adult Patients With Newly Diagnosed Therapy-Related AML or AML With Myelodysplasia-Related Changes in Greece
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02619-5&doi=10.1016/j.jval.2022.09.415
First page :
Section Title :
Open access? :
No
Section Order :
12222